Search results for "RENAL DISORDERS"

showing 10 items of 21 documents

DLG4-related synaptopathy: a new rare brain disorder

2021

Contains fulltext : 245031.pdf (Publisher’s version ) (Closed access) PURPOSE: Postsynaptic density protein-95 (PSD-95), encoded by DLG4, regulates excitatory synaptic function in the brain. Here we present the clinical and genetic features of 53 patients (42 previously unpublished) with DLG4 variants. METHODS: The clinical and genetic information were collected through GeneMatcher collaboration. All the individuals were investigated by local clinicians and the gene variants were identified by clinical exome/genome sequencing. RESULTS: The clinical picture was predominated by early onset global developmental delay, intellectual disability, autism spectrum disorder, and attention deficit-hyp…

0301 basic medicineAutism Spectrum Disorder[SDV]Life Sciences [q-bio]030105 genetics & heredityBiology03 medical and health sciencesIntellectual DisabilityIntellectual disabilitymedicineMissense mutationHumansGlobal developmental delayExomeGenetics (clinical)GeneticsBrain DiseasesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]Brainmedicine.disease030104 developmental biologyPhenotypeRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]Autism spectrum disorderNeurodevelopmental DisordersSynaptopathyDLG4Postsynaptic densityDisks Large Homolog 4 Protein
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

C2orf69 mutations disrupt mitochondrial function and cause a multisystem human disorder with recurring autoinflammation

2021

BACKGROUND. Deciphering the function of the many genes previously classified as uncharacterized open reading frame (ORF) would complete our understanding of a cell’s function and its pathophysiology. METHODS. Whole-exome sequencing, yeast 2-hybrid and transcriptome analyses, and molecular characterization were performed in this study to uncover the function of the C2orf69 gene. RESULTS. We identified loss-of-function mutations in the uncharacterized C2orf69 gene in 8 individuals with brain abnormalities involving hypomyelination and microcephaly, liver dysfunction, and recurrent autoinflammation. C2orf69 contains an N-terminal signal peptide that is required and sufficient for mitochondrial…

0301 basic medicineMicrocephalyRespiratory chainBiologyMitochondrionCell LineMitochondrial ProteinsTranscriptomeMiceOpen Reading Frames03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineLoss of Function MutationGlycogen branching enzymemedicineAnimalsHumansGeneMice KnockoutGeneticsMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Glycogen Debranching Enzyme SystemGeneral Medicinemedicine.diseaseMitochondriaOpen reading frameRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisMicrocephalybiology.proteinClinical MedicineSignal transductionGlycogenJournal of Clinical Investigation
researchProduct

Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma

2020

Contains fulltext : 235640.pdf (Publisher’s version ) (Closed access) Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analys…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsMedizinSingle-nucleotide polymorphismGenome-wide association studyBiologyAdenocarcinomaPolymorphism Single NucleotideReceptor IGF Type 103 medical and health sciencesBarrett Esophagus0302 clinical medicineRisk FactorsSomatomedinsInternal medicineGenetic variationmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseRisk factorGerm-Line MutationCancer Biomarkers and Molecular EpidemiologyInsulin-like growth factor 1 receptorGenetic associationAgedGeneral MedicineMiddle Agedmedicine.diseaseRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisBarrett's esophagusFemaleHuman medicineCarrier ProteinsGenome-Wide Association StudySignal TransductionCarcinogenesis
researchProduct

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care

2018

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life;…

2747 Transplantation030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseINTRACRANIAL ANEURYSMS610 Medicine & healthBLOOD-PRESSUREDiseaseClinical practiceGUIDELINES10052 Institute of Physiology03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineQuality of life (healthcare)NursingQUALITY-OF-LIFEPolycystic kidney diseaseMultidisciplinary approachHealth caremedicinePolycystic kidney diseaseCKDMultispecialist care030212 general & internal medicineDisease management (health)ADPKDOUTCOMESTransplantation2727 NephrologyScience & Technologypolycystic kidney diseasebusiness.industryRENAL REPLACEMENT THERAPYPATIENT PERSPECTIVESUrology & Nephrologymedicine.diseasePREVALENCEclinical practiceTransplantationRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]CLINICAL-PRACTICENephrologymultispecialist care570 Life sciences; biologybusinessLife Sciences & Biomedicine
researchProduct

KIAA0556 is a novel ciliary basal body component mutated in Joubert syndrome

2015

Background Joubert syndrome (JBTS) and related disorders are defined by cerebellar malformation (molar tooth sign), together with neurological symptoms of variable expressivity. The ciliary basis of Joubert syndrome related disorders frequently extends the phenotype to tissues such as the eye, kidney, skeleton and craniofacial structures. Results Using autozygome and exome analyses, we identified a null mutation in KIAA0556 in a multiplex consanguineous family with hallmark features of mild Joubert syndrome. Patient-derived fibroblasts displayed reduced ciliogenesis potential and abnormally elongated cilia. Investigation of disease pathophysiology revealed that Kiaa0556-/- null mice possess…

AdultMaleK04F10.2KIAA0556MicrotubuleMicrotubulesRetinaMiceJoubert syndromeCerebellumAnimalsHumansAbnormalities MultipleExomeCiliaEye AbnormalitiesSensory disorders Radboud Institute for Molecular Life Sciences [Radboudumc 12]Caenorhabditis elegansChildCells CulturedAdenosine TriphosphatasesADP-Ribosylation FactorsResearchBrainMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Kidney Diseases CysticBasal BodiesPedigreeMice Inbred C57BLRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]Basal bodyChild PreschoolMutationFemaleKataninMicrotubule-Associated ProteinsProtein BindingGenome Biology
researchProduct

Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet.

2015

Contains fulltext : 155347.pdf (Publisher’s version ) (Closed access) BACKGROUND/OBJECTIVES: In the context of obesity, epigenetic mechanisms regulate cell-specific chromatin plasticity, perpetuating gene expression responses to nutrient excess. MacroH2A1, a variant of histone H2A, emerged as a key chromatin regulator sensing small nutrients during cell proliferation and differentiation. Mice genetically ablated for macroH2A1 (knockout (KO)) do not show overt phenotypes under a standard diet. Our objective was to analyse the in vivo role of macroH2A1 in response to nutritional excess. METHODS: Twelve-week-old whole-body macroH2A1 KO male mice were given a high-fat diet (60% energy from lard…

EXPRESSIONCHROMATINNonalcoholic steatohepatitisModels Molecularmedicine.medical_specialtyHISTONE VARIANT MACROH2Amacrohistone H2A1 High fat diet obesity.Endocrinology Diabetes and MetabolismLIVER-DISEASE NAFLDTHERMOGENESISMedicine (miscellaneous)Adipose tissueBiologyDiet High-FatCell LineHistonesMiceINFLAMMATIONAdipose Tissue BrownThinnessInternal medicineBINDINGmedicineAnimalsGenetic ablationNutrition and DieteticsAdipogenesisNONALCOHOLIC STEATOHEPATITISTRANSCRIPTIONAL COREGULATOR PELP1medicine.diseaseNUTRITION&DIETETICSObesityDisease Models AnimalRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]EndocrinologyEnergy expenditureFat dietOBESITYInsulin ResistanceEnergy MetabolismThermogenesisInternational journal of obesity (2005)
researchProduct

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System : success or waste of organs? The Eurotransplant 15-year all-centr…

2016

Item does not contain fulltext BACKGROUND: In the Eurotransplant Kidney Allocation System (ETKAS), transplant candidates can be considered for high-urgency (HU) status in case of life-threatening inability to undergo renal replacement therapy. Data on the outcomes of HU transplantation are sparse and the benefit is controversial. METHODS: We systematically analysed data from 898 ET HU kidney transplant recipients from 61 transplant centres between 1996 and 2010 and investigated the 5-year patient and graft outcomes and differences between relevant subgroups. RESULTS: Kidney recipients with an HU status were younger (median 43 versus 55 years) and spent less time on the waiting list compared…

Graft RejectionMalemedicine.medical_treatmentMedizin030232 urology & nephrologygraft survival030230 surgery0302 clinical medicineSurveys and QuestionnairesDIALYSISYoung adultChildKidney transplantationCANDIDATESKidneyMiddle AgedPrognosis3. Good healthEuropeMulticenter Studymedicine.anatomical_structureNephrologyChild PreschoolFemaleHemodialysisAdultReoperationmedicine.medical_specialtykidneyTissue and Organ ProcurementAdolescentWaiting ListsDonor SelectionResource AllocationYoung Adult03 medical and health sciencespatient survivalInternal medicinemedicineJournal ArticleHumansComparative StudyRenal replacement therapyDialysisAgedbusiness.industryDonor selectionInfant NewbornInfantmedicine.diseaseKidney TransplantationSurgeryTransplantationhigh-urgencyPRIORITYSURVIVAL BENEFITrenalHuman medicineRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]businessWAITING TIMEtransplantationNephrology, dialysis, transplantation
researchProduct

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

2020

Contains fulltext : 229341.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Numerous pharmacological compounds that target the different molecular targets involved in the pathobiology of nonalcoholic steatohepatitis (NASH) are currently in clinical testing. So far, there are no regulatory approvals. AREAS COVERED: This paper sheds light on the molecular pathways involved in NASH and the drugs targeting these pathways. We have identified 10 compounds whose clinical development program has been halted. Moreover, we explore early phase clinical trials and dissect the reasons for termination of development. EXPERT OPINION: The main goal of NASH pharmacotherapy is to halt or reverse hepati…

Liver Cirrhosis0301 basic medicineNonalcoholic steatohepatitisAnti-Inflammatory AgentsPhases of clinical researchBioinformaticsdigestive system03 medical and health sciences0302 clinical medicineDrug DevelopmentNon-alcoholic Fatty Liver DiseasemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPharmacologybusiness.industryFatty liverGeneral Medicinemedicine.diseasedigestive system diseasesRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyDrug development030220 oncology & carcinogenesisMolecular targetsbusinessExpert Opinion on Investigational Drugs
researchProduct

Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies

2020

Abstract Background: Obesity is a major risk factor for esophageal adenocarcinoma (EA) and its precursor Barrett's esophagus (BE). Research suggests that individuals with high genetic risk to obesity have a higher BE/EA risk. To facilitate understanding of biological factors that lead to progression from BE to EA, the present study investigated the shared genetic background of BE/EA and obesity-related traits. Methods: Cross-trait linkage disequilibrium score regression was applied to summary statistics from genome-wide association meta-analyses on BE/EA and on obesity traits. Body mass index (BMI) was used as a proxy for general obesity, and waist-to-hip ratio (WHR) for abdominal obesity. …

Male0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsEpidemiologyQuantitative Trait LocieducationMedizinMEDLINEGenome-wide association studyAdenocarcinomaPolymorphism Single NucleotideRisk AssessmentLinkage DisequilibriumBody Mass IndexBarrett Esophagus03 medical and health sciencesSex Factors0302 clinical medicineMeta-Analysis as TopicRisk FactorsInternal medicineHumansMedicineGenetic Predisposition to DiseaseObesityEsophagusWaist-Hip Ratiobusiness.industryEsophageal cancermedicine.diseaseMedical researchObesityRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisBarrett's esophagusDisease ProgressionAdenocarcinomaFemalebusinessGenome-Wide Association StudyCancer Epidemiology, Biomarkers & Prevention
researchProduct